{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:59:41Z","timestamp":1792421981789,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T00:00:00Z","timestamp":1169596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Head &amp; Neck"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background.<\/jats:title><jats:p>The optimal drug schedule and sequencing of chemotherapy and radiation for organ preservation in head and neck cancer has yet to be determined. We undertook a phase II trial of a taxane\u2010based induction chemotherapy (ICT) followed by a taxane\u2010based concurrent chemoradiation (CCR) regimen in patients with resectable stage III or IV disease to determine the feasibility, toxicity, and overall efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Forty\u2010four patients with laryngeal or tongue base carcinomas were enrolled. All patients received 3 cycles of chemotherapy with paclitaxel 175 mg\/m<jats:sup>2<\/jats:sup> and carboplatin AUC (area under the curve) 6\u20137.5 over 30 minutes on days 1, 22, and 43. Responding patients went on to receive radiation (70 Gy\/7 weeks) with cisplatin 75 mg\/m<jats:sup>2<\/jats:sup> IV on days 1, 22, and 43 and weekly paclitaxel 30 mg\/m<jats:sup>2<\/jats:sup> IV (<jats:italic>n<\/jats:italic> = 22). Because of hematologic toxicity, the concurrent regimen was changed to weekly carboplatin AUC 1 plus weekly paclitaxel 30 mg\/m<jats:sup>2<\/jats:sup> (<jats:italic>n<\/jats:italic> = 22).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Twenty\u2010three patients with stage III and 21 patients with stage IV disease were enrolled. Median follow\u2010up was 3.7 years. Acute toxicity of concurrent cisplatin and paclitaxel was excessive, with significant hematologic toxicity and 2 toxic deaths. Acute toxicities of concurrent carboplatin and paclitaxel were tolerable. No patients required permanent percutaneous gastrostomy tubes. The organ preservation rate was 83% (toxic deaths considered failures). Of 42 evaluable patients, 20 patients had complete responses (48%), 17 partial responses (41%), 3 minor responses (11%), 1 stable disease (2%), and 1 progressive disease (2%). Two\u2010year local control, relapse\u2010free survival, and overall survival were 82%, 77%, and 71%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>There were no significant differences in relapse\u2010free survival or organ preservation rates between concurrent regimens. Platinum and paclitaxel\u2010based CCR is feasible after ICT and provides a high rate of organ preservation. Substitution of concurrent cisplatin to weekly carboplatin with paclitaxel and radiation has an improved toxicity profile. The ease of administration and low toxicity make this a regimen that is practical for use in the community setting. \u00a9 2007 Wiley Periodicals, Inc. Head Neck, 2007<\/jats:p><\/jats:sec>","DOI":"10.1002\/hed.20522","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T05:37:03Z","timestamp":1169703423000},"page":"315-324","source":"Crossref","is-referenced-by-count":21,"title":["Taxane\u2010based chemoirradiation for organ preservation with locally advanced head and neck cancer: Results of a phase II multi\u2010institutional trial"],"prefix":"10.1002","volume":"29","author":[{"given":"Anthony J.","family":"Cmelak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Burkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Netterville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"United States Cancer Statistics: 2002 Incidence and Mortality","author":"U.S. Cancer Statistics Working Group","year":"2002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106133242402"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.890"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.126.2.229"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(80)80069-9"},{"key":"e_1_2_6_7_2","first-page":"289","article-title":"A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck","volume":"12","author":"SECOG","year":"1986","journal-title":"Eur J Surg Onc"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.9.1410"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(89)90362-3"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900415)65:8<1685::AID-CNCR2820650804>3.0.CO;2-S"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(90)90342-H"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910215)67:4<915::AID-CNCR2820670410>3.0.CO;2-8"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210153271602"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1318"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO;2-Y"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806183382503"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.021"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1310"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00157-6"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00321-6"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90098-O"},{"key":"e_1_2_6_22_2","first-page":"838","article-title":"Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta\u2010analysis of prospective and randomized trials","volume":"14","author":"El\u2010Sayed S","year":"1996","journal-title":"Clin Oncol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.17"},{"key":"e_1_2_6_24_2","first-page":"386a","article-title":"Meta\u2010analysis of chemotherapy in head and neck cancer (MACH\u2010NC): (1)loco\u2010regional treatment vs. same treatment + chemotherapy (CT)","volume":"17","author":"Bourhis J","year":"1988","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031317"},{"key":"e_1_2_6_26_2","first-page":"385a","article-title":"Intensive concomitant chemo\/radiotherapy (CR\/XRT) for head and neck cancer (HNC): high locoregional control and organ preservation (op) rates","volume":"17","author":"Vokes EE","year":"1998","journal-title":"Proc ASCO J Clin Oncol"},{"key":"e_1_2_6_27_2","first-page":"181","article-title":"Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial","volume":"15","author":"Forastiere A","year":"1993","journal-title":"J Natl Cancer Inst Monogr"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855010-00002"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(96)04398-4"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1278-3218(99)80034-1"},{"key":"e_1_2_6_31_2","first-page":"5198","article-title":"Paclitaxel enhances in vitro radiosentivity of squamous cell lines of the head and neck","volume":"56","author":"Leonard CE","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_6_32_2","first-page":"1516","article-title":"Carboplatin and taxol as induction therapy for locally advanced carcinoma of the head and neck","author":"Dang TP","year":"1998","journal-title":"Proc ASCO"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900801)66:3<564::AID-CNCR2820660326>3.0.CO;2-D"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.1990"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.026"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.006"},{"key":"e_1_2_6_37_2","doi-asserted-by":"crossref","first-page":"502s","DOI":"10.1200\/jco.2005.23.16_suppl.5509","article-title":"A phase II trial of chemoradiation (CR) for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx (L) or oropharynx (OP): a trial of the Eastern Cooperative Oncology Group (E2399)","volume":"23","author":"Cmelak AJ","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_38_2","doi-asserted-by":"crossref","first-page":"509s","DOI":"10.1200\/jco.2005.23.16_suppl.5536","article-title":"Intensity\u2010modulated radiation therapy (IMRT) with concurrent taxane\u2010based chemotherapy for locally advanced head and neck cancer (LAHNC): feasibility, technique, and toxicities","volume":"23","author":"Duggan D","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_39_2","first-page":"285s","article-title":"Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000\u201001","volume":"24","author":"Calais G","year":"2006","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhed.20522","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.20522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T15:15:29Z","timestamp":1697642129000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.20522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1002\/hed.20522"],"URL":"https:\/\/doi.org\/10.1002\/hed.20522","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,24]]}}}